Objective: To assess the efficiency of target-enrichment next-generation sequencing (NGS) with copy number assessment in inherited neuropathy diagnosis.
conventional Sanger sequencing to detect mutations has become impractical owing to the large list of causal genes and high cost. The high cost in polyneuropathy evaluation needs to be addressed as the average Medicare expenditure was $14,362 in the year that the diagnosis of a polyneuropathy was made. 2 Next-generation sequencing (NGS) provides a powerful tool for both genetic research and potentially clinical diagnosis. 14, 15 One NGS application, whole exome sequencing (WES), screens the transcribed regions of all known genes. We previously explored WES utility in patients with undiagnosed inherited polyneuropathy and found that 21% had pathogenic nucleotide mutations. 16 The discoveries from WES have also broadened gene-specific phenotypes. 17, 18 Despite the benefits, the current use of WES as a routine clinical test in polyneuropathy is suboptimal because of its performance metrics (such as depth of coverage), cost, and the difficulty in analysis. Furthermore, complex strategies in reporting and consenting individuals undergoing WES or whole genome sequencing are needed to address ethical issues when unexpected mutations are found in genes unrelated to the disease. 19 We investigate the effectiveness of a custom-designed targeted NGS approach to identify nucleotide mutations, small insertion/deletions, and large copy number changes such as PMP22 gene duplications for inherited polyneuropathy. The current technology combined with past experience prompts us to consider a new algorithm incorporating targeted NGS approach to improve the efficacy of polyneuropathy diagnosis in clinical practice.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by our institutional review board. Patients provided written consent. We identified cases without known genetic cause and suspected to have inherited polyneuropathy with or without family history.
Targeted enrichment design. We designed a SureSelect Target-Enrichment kit (Agilent Technologies, Santa Clara, CA) for diagnostic testing of all types of hereditary neuropathies. This panel covers 197 genes (table e-1 on the Neurology ® Web site at Neurology.org) and is part of a larger neuromuscular gene capture design also including genes for dystrophies such as those caused by deletions of the DMD gene. A total of 5,940 targets were included. We performed paired-end 101bp sequencing on HiSeq2000 (Illumina, San Diego, CA). Because all the targeted regions only cover less than 2M base, we indexed 48 samples per lane and still achieved high-depth coverage.
Bioinformatics analysis. Bioinformatics analysis was performed using GenomeGPS, a comprehensive analysis pipeline developed at Mayo Clinic. 16 We filtered the variants using Ingenuity Variant Analysis (Qiagen, Venlo, Netherlands). The variants were filtered and annotated using dbSNP (build144), OMIM, 1KGenome, ESP6500, Exac databases, and Ingenuity community collected exome database totaling ;100,000 samples of which ;86,000 are exomes and 14,000 are whole genome sequencing, as well as Human Genome Mutation Database. Nonsynonymous/splicing variants were evaluated by Polyphen2, SIFT, and Genomic Evolutionary Rate Profiling score. The identified mutations and novel variants (minor allele frequency [MAF] ,0.0001, SIFT or Polyphen2 damaging) were Sanger sequence confirmed.
Copy number analysis. We also developed a new copy number variation (CNV) detection algorithm (PatternCNV) to assess CNV with improved sensitivity/specificity and increased resolution compared to other approaches. 20 To validate our copy number detection algorithm, we include 1 sample with PMP22 duplication and 2 samples with DMD deletions. The identified copy number mutations and novel CNV variants were confirmed using CytoScan (Affymetrix, Santa Clara, CA) in our CLIAcertified laboratory.
Cost analysis. We evaluated the cost of earlier evaluations using 4 categories: (1) electrophysiologic studies; (2) laboratory tests such as complete blood cell count, urinalysis routine, serum vitamin B 12 assay, fasting glucose, hemoglobinA1C, protein electrophoresis, high sensitivity thyrotropin, sedimentation rate, lipid panel, and rheumatoid factor, autoimmune testing such as paraneoplastic antibody evaluation, and pathologic testing such as abdominal fat aspiration and sural nerve biopsy; (3) imaging testing, including x-ray bone survey, and brain or spinal MRI; and (4) selected candidate gene testing by Sanger sequencing or multiplex ligation amplification for copy number change. Only costs at our institution ordered to define the etiology of the polyneuropathy were calculated. RESULTS Included cases. We identified 93 randomly selected genetically unresolved cases from our Neuropathy DNA Sample bank, including the following: hereditary motor and sensory polyneuropathy (HMSN) type 2 (HMSN2; n 5 80); HMSN1 (n 5 1); HMSN unclassified (n 5 3); chronic idiopathic axonal polyneuropathy (n 5 6), defined as polyneuropathy with distal leg sensory predominant symptoms, without family history 21, 22 ; and hereditary motor neuropathy (n 5 3). The mean age at the initial evaluation was 54 years (range 2-86), and the mean age at polyneuropathy onset was 41 years (range 2-85). Varied extent of family history of polyneuropathy was reported in 51 of 93 patients. Among these 51 patients, 37 reported similar weakness or sensory symptoms in one or more of their family members, and 14 had high arches with/without hammertoes or skinny legs.
Coverage of targeted polyneuropathy genes. We obtained high-quality calls. Eighty-five percent reads have Phred-Score .30 and average coverage depth of 7603 for 5,940 regions (median 5 6003). Almost all targeted regions (5,905, 99.4%) had .1003 average coverage depth (figure e-1). Among 35 regions ,1003 depth, 20 had ,253. Of note, 18 of these 20 regions are in introns or untranslated region; the reason some targeted regions fall into introns is that our design requested 25bp surrounding sequence of exons. All undercovered regions overlap with repetitive elements that are difficult for all sequencing platforms.
Copy number change identification. Our analysis successfully detected the copy number mutations in 3 controls: one covering the entire PMP22 gene region (;1.4 MB), one large DMD deletion (exon 2-exon 45, ;633 kb), and a small DMD deletion (exon 46exon 47, ;3 kb), matching the findings from clinical testing (figure e-2).
Among 93 cases, we detected 3 CNV mutations: PMP22 duplications (P2 and P78) (see chromosomeand gene-level graphs in figure 1A ) and MPZ gene duplication (P46) within a large Chr1q duplication ( figure 1B) . MPZ duplication has been recently reported to cause hereditary neuropathy. 23 The unexpected PMP22 duplications occurred in 2 HMSN2labeled patients with onset in toddler years after initially making normal motor milestones; however, their electrophysiologic evaluations were done ;30 years after onset, when they had severe phenotypes with flail hands, wheelchair-assisted and needing nocturnal respiratory support. Nerve conductions were absent in the feet and hands but proximal stimulation and blink responses were not performed.
Pathogenic mutation identifications. We identified 15 nucleotide pathogenic mutations in 14 cases (1 case had mutations in both MPZ and MFN2). Combined with the aforementioned 3 cases with copy number mutations of PMP22, and MPZ, a total of 17 cases (18%) obtained genetic discovery. Eleven of them had previously negative candidate gene testing. Among these 17 cases, the mean onset age is 25 years (range 2-61), and the mean age at initial evaluation is 42 years (range 2-69). Among them, 12 patients (71%) had familial occurrence or tendency, of which 9 reported similar symptom in family members, and 3 reported family members with high arches with/without hammertoes or skinny legs. The identified mutations are summarized in table 1.
Although almost all 17 patients were previously diagnosed with or suspected to have HMSN2, our results indicate that 5 actually have HMSN1, 1 has HSAN1, 1 has giant axonal neuropathy, and 1 has Fabry disease. Three patients with mutations in EGR2 and GJB1 had been thought to have HMSN2 because their EMG revealed either no response or very low amplitude at upper limb ulnar motor nerve conduction (,0.1 mV), and they all had long disease duration (.30 years). The 1 patient with a GJB1 mutation had a severe axonal polyneuropathy on EMG results with intermediate slowing. The HSAN1 patient with SPTLC1 mutation had prominent length-dependent motor nerve involvement, but no obvious foot ulcer or family history. The giant axonal polyneuropathy patient with a homozygous GAN mutation initially presented with early-onset axonal sensorimotor polyneuropathy and unclear family history since he was adopted. Neuropathy has been reported in patients with GAN mutation. 24 The 2 cases with MPZ nucleotide mutations were determined to have Charcot-Marie-Tooth (CMT) 2I based on further clinical review; 1 also had a MFN2 mutation. The patient with a BAG3 mutation was diagnosed with HMSN2 with adolescence-onset polyneuropathy, signs of distal atrophy in the legs, high arches, and curled toes. Dominant BAG3 mutations typically cause myofibrillar myopathy or cardiomyopathy, but recently a BAG3 mutation was found to cause an axonal sensorimotor polyneuropathy with giant axons. 25 The male patient with a hemizygous mutation GLAp.M1L (damaging by SIFT and Polyphen2) is recognized in retrospect to have Fabry disease with significant small-fiber involvements but without angiokeratomas. Five mutations at this position, GLAp.M1R, M1I, M1K, M1T, and M1V, were previously reported in patients with Fabry disease. [26] [27] [28] Rare variants and CNVs. In addition to 18 pathogenic mutations, we also identified 4 rare variants and 2 novel copy number changes in 6 cases, occurring in AARS, LRSAM1, KIAA0196, DCTN1, SPAST, and TRIM2. These nucleotide variants are either absent or have MAF ,0.0001 in variant databases (1KGenome, dbSNP, Exac, and Ingenuity Community Database). They occurred at highly conserved positions and are predicted damaging (table 2). In addition, 1 case (P43) was found with SCN11Ap.L1158P (MAF in Exac 5 0.06), a previously reported mutation for small fiber neuropathy, 29 although the patient did not have any phenotype of small fiber neuropathy. We did not include rare heterozygous variants found in the genes only linked to recessive disorders or CNVs that have been reported in Database of Genomic Variants (DGV). For the 6 patients with rare, damaging variants, the average onset age is 35 years (range 3-63), the average age at initial evaluation is 45 years (range 17-67), and 2 had family history. For the remaining 70 cases (75%) without causal mutation or rare damaging variant, the average onset age is 45 years (range 4-85) and the average age at initial evaluation is 58 years (range 11-86), indicating that genetic diagnosis remains to be found in the majority of patients with inherited axonal polyneuropathy (figure 2, A and B). 30 The novel CNV of SPAST and TRIM2 (figure e-3) are not in DGV, and their disease association needs further investigation. ) , and randomly selected 10 patients who had candidate gene testing, 5 with (group 1) and 5 without (group 2) family history. The average cost of their clinical evaluation is summarized (table e-2). The average cost of a comprehensive evaluation with unclear etiology is estimated at ;$13,000, similar to prior report. 2 The average cost of earlier candidate gene testing is ;$2,800 (;$250-$8,500), and the most commonly screened genes were those recommended in earlier diagnostic algorithms PMP22, MPZ, GJB1, and MFN2. 13 Because the current reagent cost of our targeted NGS approach is ;$100, if the test is utilized routinely in the clinical setting, the cost of this comprehensive screening will be only a small fraction of candidate gene testing and the diagnosis rate can be improved. Using the data from the cost evaluation and diagnostic yield, we calculated the potential cost saving of utilizing NGS testing (table e-3) . Specifically, if we estimate that targeted NGS testing costs $1,000-$1,500 per sample, with observed positive test rate of 20%, a cost savings of 8%-12% is achieved. If we focus on those with early-onset age and family history, the cost savings rise to 17%-21%. DISCUSSION We designed a comprehensive inherited polyneuropathy evaluation that can handle an expanding genotype-phenotype complexity with increased efficiency at reduced cost. The comprehensive nature of this NGS approach reduces the need to order genetic testing based on the outcome of nerve conduction studies (axonal, demyelinating, intermediate). Our study indicates that clinical complexity or severity can incorrectly restrict candidate gene testing by clinical phenotypes or electrophysiologic categorization. Specifically, the genetic cause is often outside the original clinical diagnostic category, as shown in almost half of our patients with identified mutation. These genetic discoveries have significant implications to the affected patients and their families. For example, the patient with Fabry GLA mutation, previously diagnosed with HMSN2, is now known to have X-linked inheritance, and requires heart and kidney monitoring and consideration for enzyme replacement therapy. Similarly, the patient found to have a SPTLC1 pathogenic mutation with intermediate nerve conduction slowing will need vigilant foot care to avoid mutilating ulcers, and can now consider participation in clinical trials using serine supplementation. 31 One concern among physicians is that large targeted panel sequencing will result in many variants of unclear significance (VUS). We only found 7 VUS in 93 cases (table 2) , and some of these VUS may lead to new genetic discoveries with further research investigations. Importantly, by incorporating a newly developed CNV algorithm we are also able to screen for PMP22 duplications, the most common CMT cause. 13 This was especially helpful in 2 patients with PMP22 duplication previously diagnosed with severe axonal disease. The copy number algorithm also identified a gene duplication of MPZ, which is recently recognized as a pathogenic mutation of HMSN1. 23, 32 This would have been missed by traditional Sanger sequencing. Our targeted NGS approach combined with an effective CNV analysis can accurately detect the copy number changes at a single exon level, and serve as a comprehensive screening test for all types of polyneuropathy, including CMT1A. Furthermore, our study emphasizes the importance of considering genes outside of those typically ordered by commercial testing, as 8 of 17 (47%) would have been missed by testing only the most commonly mutated genes: PMP22, MFN2, MPZ, and GJB1. 13 Based on the results of this study and the earlier published practice guidelines for polyneuropathy, 12 we propose a new diagnostic algorithm that utilizes the targeted NGS approach, onset age, family history, and bedside clinical findings to increase the efficacy of a polyneuropathy evaluation for inherited cause (figure 3 ). Since CMT1A is the most common type of hereditary neuropathy, if the patient underwent EMG study and showed uniform demyelinating with reduced conduction velocity (,35 m/s), PMP22 duplication/deletion should still be considered as the first ordered test. Our results indicate that onset age appears to be a strong predicting factor for obtaining genetic diagnosis ( figure 2A) . The mean onset age of our patients with pathogenic mutations is much younger than that of patients with unclear etiology (25 years vs 45 years). Among slowly progressive and length-dependent polyneuropathy patients with early onset age, the NGS test positive rate is high at 27% ( figure 2B ). Even without family history, the diagnostic rate was at 20% among those with ,40 years onset age. The diagnostic rate is also high for those with family history at 24%. Family history is useful but not necessary for genetic discovery. Among the 93 evaluated cases, 51 (55%) had family history, of which 24% (12/51) were identified with pathogenic mutations, but 12% (5/42) of cases without family history also had pathogenic mutations. In addition, the family history described here is not always extensive or definitive; many patients only mentioned family members with high arches, hammertoes, or skinny legs. Although considered somewhat subjective, high arches have been reported to have ;40% possibility of having inherited polyneuropathy. 33 Not surprisingly, those with early onset and family history had the highest diagnosis rate (33%). But only 1 of 22 patients with onset age of .40 years and no family history had genetic discovery. Thus, we suggest performing targeted NGS initially for those with young onset age or family history. Additionally, all patients should be tested for diabetes, monoclonal gammopathy, and B 12 deficiency, as they may further The proposed diagnostic algorithm
The proposed algorithm for evaluating chronic slowly progressive length-dependent polyneuropathy utilizing targeted nextgeneration sequencing copy number evaluation, age at onset, and family history along with knowledge of inherited neuropathy phenotypes to determine testing. A negative or inconclusive evaluation prompts consideration of CIAP or research studies by whole exome sequencing/genome sequencing. *All adult patients undergo testing for HgBA1c or glucose tolerance, monoclonal proteins, and B 12 deficiency.
worsen existing inherited polyneuropathy and the tests are inexpensive. 34, 35 However, unless there is specific clinical suspicion or indication, other laboratory tests can be delayed after the targeted NGS test. For patients with onset age .40 years and without family history, clinical phenotypes associated with inherited neuropathies, i.e., motor, large fiber sensory, large and small fiber sensory loss, can direct further appropriate evaluation. 4 Specifically, motor predominant phenotypes are far more likely to have inherited cause; when large fiber sensory and pyramidal signs features are predominant, spinocerebellar syndromes should be considered. At present, repeat expansions cannot readily be assessed by targeted NGS, and MRI for cerebellar atrophy is often helpful in making the diagnosis. Inherited disorders with Mendelian cause frequently have early onset relating to the strong deleterious influences of their pathogenic mutations. 35, 36 Cases with late onset have reduced likelihood of finding a genetic cause, highlighting the longstanding polygenic enigma of chronic idiopathic axonal polyneuropathy (CIAP). 37 In this study, no patients with CIAP phenotypes had pathologic mutations, consistent with evidence-based practice guidelines discouraging genetic testing in them. 12 However, accurately determining the age at onset can be difficult and careful clinical judgment is emphasized. In this study, we found the mean disease duration from the symptom onset to the first evaluation at our hospital is ;15 years. This further emphasizes the importance of affordable and comprehensive genetic testing available to general neurologists. When uncertainties remain, neuromuscular experts should be involved to assist in deep phenotyping, data interpretation, and potential kindred evaluations based on VUS discoveries.
The technology of NGS has evolved whereby we can appreciate meaningful clinical benefits. Our analysis suggests that the cost saving of utilizing targeted NGS testing with copy number evaluation will be significant. The actual savings could be greater than our calculation as we excluded patients with earlier positive gene testing of the most common phenotype-genotype associations. 13 Targeted NGS approach combined with copy number analysis will expedite polyneuropathy diagnosis, reduce unnecessary treatments and testing, and allow clinicians to provide effective disease management, treatment, and research efforts. Our findings prompt a need for updating the current practice parameters and payer guidelines with respect to genetic testing for hereditary neuropathies.
